Latest research on Octreotide

Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.

Octreotide side effects

The combined application of corticosteroids with Octreotide may reduce the required dosage of Octreotide, avoid the side-effects and ease the financial burden of the patient. [source, 2016]
Similarly, when the insulin infusion rate was increased to 40 mU m2 min−1, along with AA infusion AT 10 g h−1 to create a fed state condition, no difference in steady-state serum insulin concentration was observed, although there was a trend for the area under the steady-state insulin curve to be greater in the statin user group (Fig. 4A, P = 0.07), probably reflecting blunted insulin clearance in statin myalgic subjects, given that endogenous insulin production was suppressed by Octreotide infusion (see Methods). [source, 2015]
Octreotide was increased to 15 mcg/kg/day, with subsequent improvement but not resolution of hypoglycemia. [source, 2015]
Octreotide, a somatostatin analog, was reported to reduce both hyperinsulinemia and BMI in a double-blind placebo-controlled study; however, it supports weight stability only in patients with profound hyperinsulinemia and is limited by significant side effects [29]. [source, 2015]
A statistically significant decrease in cell proliferation was observed in GC tumor cultures treated with Octreotide and BIM-23120, but not with SOM-230 (Fig. 5C). [source, 2015]
In GC primary tumor cultures we observe that Octreotide and BIM-23120, but not SOM-230, cause a decrease in cell proliferation. [source, 2015]
Octreotide is a somatostatin analogue that decreases mesangial expansion and albuminuria in DM animal models [161]. [source, 2015]
Octreotide was started S/cly at a dose of 5 µg/kg/d 8 hrly with doses being gradually increased to 30 µg/kg/d 6 hrly. [source, 2015]
This was well-tolerated with no side effects like hypotension and the baby was euglycaemic with no pre-feed or early morning hypoglycaemia on a combination of oral Nifedipine and S/c Octreotide. [source, 2015]
Until now, somatostatin analogues, such as Octreotide Acetate, were identified as effective compounds for patients with carcinoid tumors [38] and may show an enhanced effect in combination with cyclin inhibitors, because a cumulative effect was reported when therapy regimen contained palbociclib in combination with other drugs [13]. [source, 2015]